452 related articles for article (PubMed ID: 12956617)
21. Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.
Vig S; Seibert L; Green MR
J Cancer Res Clin Oncol; 2014 Jan; 140(1):77-82. PubMed ID: 24173694
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
Slatkin NE
J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
[TBL] [Abstract][Full Text] [Related]
23. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.
Jordan K; Roila F; Molassiotis A; Maranzano E; Clark-Snow RA; Feyer P;
Support Care Cancer; 2011 Mar; 19 Suppl 1():S37-42. PubMed ID: 20824481
[TBL] [Abstract][Full Text] [Related]
24. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
25. Optimal selection of antiemetics in children receiving cancer chemotherapy.
Roila F; Aapro M; Stewart A
Support Care Cancer; 1998 May; 6(3):215-20. PubMed ID: 9629872
[TBL] [Abstract][Full Text] [Related]
26. [Research on antiemetics: an Italian model of success].
Roila F
Tumori; 1998; 84(1 Suppl):S3-11. PubMed ID: 9617377
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Rojas C; Slusher BS
Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
[TBL] [Abstract][Full Text] [Related]
28. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
Schwartzberg LS; Jacobs P; Matsouka P; Azevedo W; Pinto A
Crit Rev Oncol Hematol; 2012 Jul; 83(1):59-70. PubMed ID: 22321726
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
Trigg ME; Higa GM
J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
[TBL] [Abstract][Full Text] [Related]
32. Practical management of chemotherapy-induced nausea and vomiting.
Wiser W; Berger A
Oncology (Williston Park); 2005 Apr; 19(5):637-45. PubMed ID: 15945344
[TBL] [Abstract][Full Text] [Related]
33. Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.
Wickham R
Cancer Control; 2012 Apr; 19(2 Suppl):3-9. PubMed ID: 22488022
[TBL] [Abstract][Full Text] [Related]
34. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
35. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
Schwartzberg LS; Rugo HS; Aapro MS
Clin Adv Hematol Oncol; 2015 Mar; 13(3 Suppl 3):3-13, 1; quiz 2 p following 14. PubMed ID: 25856052
[TBL] [Abstract][Full Text] [Related]
36. Antiemetics in children receiving cancer chemotherapy.
Billett AL; Sallan SE
Support Care Cancer; 1994 Sep; 2(5):279-85. PubMed ID: 8000723
[TBL] [Abstract][Full Text] [Related]
37. Prevention of gastrointestinal side-effects in paediatric oncology: what are the guidelines?
Cheng KKF
Curr Opin Support Palliat Care; 2017 Jun; 11(2):120-124. PubMed ID: 28333866
[TBL] [Abstract][Full Text] [Related]
38. New treatment options for chemotherapy-induced nausea and vomiting.
Hesketh PJ
Support Care Cancer; 2004 Aug; 12(8):550-4. PubMed ID: 15232725
[TBL] [Abstract][Full Text] [Related]
39. Delayed nausea and vomiting from carboplatin doublet chemotherapy.
Waqar SN; Mann J; Baggstrom MQ; Waqar MA; Chitneni P; Williams K; Gao F; Morgensztern D; Govindan R
Acta Oncol; 2016 Jun; 55(6):700-4. PubMed ID: 27145068
[TBL] [Abstract][Full Text] [Related]
40. Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence?
Antonarakis ES; Evans JL; Heard GF; Noonan LM; Pizer BL; Hain RD
Pediatr Blood Cancer; 2004 Nov; 43(6):651-8. PubMed ID: 15390297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
